Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients
Cancer Medicine · 2025
DOI: 10.1002/cam4.70501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Valentina Salvestrini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Gastrointestinal Microbiome, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Background
The management of acute myeloid leukemia (AML) is hindered by treatment‐related toxicities and complications, particularly cytopenia, which remains a leading cause of mortality. Given the pivotal role of the gut microbiota (GM) in hemopoiesis and immune regulation, we investigated its impact on hematologic recovery during AML induction therapy.
Methods
We profiled the GM of 27 newly diagnosed adult AML patients using 16S rRNA amplicon sequencing and correlated it with key clinical parameters before and after induction therapy.
Results
Our investigation revealed intriguing associations between the GM composition and crucial recovery indicators, including platelet, lymphocyte, and neutrophil counts, and identified early GM signatures predictive of improved hematologic recovery. Remarkably, patients demonstrating superior recovery had higher alpha diversity and enrichment in health‐associated taxa belonging to the genera Faecalibacterium , Ruminococcus , Blautia , and Butyricimonas at diagnosis.
Conclusions
Despite certain study limitations, our findings suggest that evaluating GM features could serve as a potential marker for hematologic recovery. This preliminary work opens avenues for personalized risk assessment and interventions, possibly involving GM modulation tools, to optimize recovery in AML patients undergoing induction therapy and potentially enhancing overall outcomes in individuals with hematologic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Human Microbiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
- Oncology and Haematology Research Area, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
ORCID-Profile: Valentina Salvestrini
Förderung
- Ministero della Salute
Zitieren
APA
Salvestrini, V., Conti, G., D'Amico, F., Cristiano, G., Candela, M., Cavo, M., Turroni, S., & Curti, A. (2025). Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients. Cancer Medicine. https://doi.org/10.1002/cam4.70501
Vancouver
Salvestrini V, Conti G, D'Amico F, Cristiano G, Candela M, Cavo M, et al. Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients. Cancer Medicine. 2025. doi:10.1002/cam4.70501
BibTeX
@article{Salvestrini2025,
author = {Salvestrini, Valentina and Conti, Gabriele and D'Amico, Federica and Cristiano, Gianluca and Candela, Marco and Cavo, Michele and Turroni, Silvia and Curti, Antonio},
title = {Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70501}
}
EUVIMED